Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Live Tissue Connect's VAD system

This article was originally published in Clinica

Executive Summary

Live Tissue Connect's VAD system has received US FDA 510(k) clearance. The system, intended for use in open general surgical and gynaecological procedures, comprises the VAD.400 bipolar electrosurgical generator and two disposable sealing instruments. It employs radiofrequency technology to bond tissue in live organs, and can reconnect soft tissue through fusion, unlike conventional wound closing devices like sutures and staples. VAD.400 can be used on veins and arteries with a diameter of up to 7mm and ducts up to 2mm in diameter. LTC, a subsidiary of Corpus Christi, Texas-based CSMG Technologies, CE marked the system for sale in Europe in December 2007 (see Clinica No 1285, p 18).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041975

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel